| October 01, 2016 to September 30, 2018 | Successful Completion of ITF Project on "Second Development of Yi-Shen-Hua-Shi Granules" in Collaboration with Consun Pharmaceutical Group A collaborative Innovation and Technology Fund (ITF) project, "Research on the Second Development of Yi-Shen-Hua-Shi Granules (UIM/290)," has been successfully completed. The project was a partnership with Consun Pharmaceutical Group Limited and its shareholder company, Century International Develop Limited, aimed at advancing a key treatment for chronic glomerulonephritis. Consun Pharmaceutical Group has previously marketed Yi-Shen-Hua-Shi granules, a proprietary drug that has shown good clinical efficacy in managing the disease. However, its widespread clinical use has been hampered by a large required dosage and an unclear mechanism of action. This research project focused on developing a new, improved dosage form for the drug. The collaboration successfully completed comprehensive preclinical studies, including quality control, stability, toxicology, pharmacodynamics, and molecular mechanism analyses for the new formulation. Key deliverables from the project include:
The successful completion of these preclinical studies enhances the technological innovation capabilities of Consun Pharmaceutical Group. This development is expected to ultimately benefit patients suffering from chronic glomerulonephritis by providing a more effective and convenient treatment option. |
| February 05, 2015 | HKBU receives HK$5 million donation from Consun Pharmaceutical Group Limited to establish The Consun Chinese Medicines Research Centre for Renal Diseases HKBU receives HK$5 million donation from Consun Pharmaceutical Group Limited to establish The Consun Chinese Medicines Research Centre for Renal Diseases on Feb 5th, 2015. |